Novotech Publishes Candidiasis and Rheumatoid Arthritis Clinical Trial Landscape Reports to Support Biotech Research Planning
11 févr. 2024 21h26 HE
|
Novotech
Novotech CRO has released today two industry-leading reports on the Candidiasis and Rheumatoid Arthritis clinical trial landscapes.
Global Antifungal Drugs Market Is Expected to Reach $25.0 Billion by 2030: Allied Market Research
23 juin 2022 07h58 HE
|
Allied Market Research
Portland, OR, June 23, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Antifungal Drugs Market generated $16.6 billion in 2020, and is projected to...
Cidara Provides Corporate Update and Reports Second Quarter 2019 Financial Results
08 août 2019 16h07 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 07h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafungin
29 juil. 2019 07h00 HE
|
Cidara Therapeutics, Inc.
Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections ...
Cidara Provides Corporate Update and Reports First Quarter 2019 Financial Results
09 mai 2019 16h13 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
03 avr. 2019 16h04 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
Cidara Therapeutics Announces Offering of Common Stock and Warrants
21 mai 2018 07h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has...
Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Common Stock
19 oct. 2017 09h00 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing...
Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Results
09 août 2017 16h31 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...